Advertisement
Collaboration › Details
JSR Corp–Berkeley Lights: cell line development, 201810– collab integrating SUREtechnology of Selexis with Beacon platform of BLI
Period | 2018-10-18 | |
Partner, 1st | Selexis S.A. | |
Group | JSR Corporation (Group) | |
Partner, 2nd | Berkeley Lights Inc. (Nasdaq: BLI) | |
Today | PhenomeX Inc. (CELL) | |
Group | Bruker (Group) | |
Product | Beacon® optofluidic platform | |
Product 2 | SUREtechnology Platform™ (Selexis) | |
Selexis S.A.. (10/18/18). "Press Release: Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform". Geneva.
Effort Designed to Safely and Efficiently Speed Drug Candidates into the Clinic
Selexis SA and Berkeley Lights, Inc. today announced a collaboration around the acquisition of Berkeley Lights’ Beacon® optofluidic platform. The partners will leverage the technology to accelerate cell line development (CLD) with the Selexis SUREtechnology Platform™. Selexis scientists have extensively evaluated the Beacon technology and will now further incorporate it into the SUREtechnology Platform workflow. Utilizing the Beacon’s optofluidic and single cell analysis technology, the Selexis team has significantly shortened the time required to identify and select the optimal cell line manufacturing clones within the CLD process.
“We are very enthusiastic about the timeline advantages that the Beacon platform will bring to our SUREtechnology Platform,” said Igor Fisch, PhD, chief executive officer of Selexis. “This optofluidic technology helps us continually improve and accelerate cell line development. Our client partners consider every month of lead time ahead of a competitor to be a significant advantage. We believe we will be able to give our partners a strong first-in-human (FIH) and first-to-market (FTM) head start while helping them deliver much-needed medicines to patients.”
Selexis’ SUREtechnology Platform is based upon optimized epigenetic DNA-based elements (Selexis Genetic Elements) that protect integrated transgenes from the transcription silencing effects of surrounding chromatin, allowing for robust production levels of protein therapeutics. This technology eliminates the need for large-scale screening to identify high-producing clones; allowing for research cell bank generation in as little as 14 weeks. Of that 14-week development time, subcloning and optimal clone identification still typically require four to eight weeks. By integrating the Beacon technology into the SUREtechnology Platform and by adapting a unique and proprietary cell clone prediction tool, the Company will be able to shave off several weeks in the development of a research cell bank, thereby speeding the development of high-quality drug product to the clinic.
“We are very pleased to be working with Selexis and value our collaboration that led to the optimization of the Beacon platform for use with the SUREtechnology Platform,” said Andy Last, PhD, chief commercial officer, at Berkeley Lights, Inc. “We are quite proud of the success of the Beacon platform in providing unparalleled single cell analytic and isolation technologies to accommodate the breadth of needs across the cell line development field.”
About Selexis SA
Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 100 drug products in clinical development and the manufacture of three commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry. More information is available at www.selexis.com.
About Berkeley Lights
?Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell-based products and therapies. At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows. Each workflow provides a 100-fold increase in insights, 10 times faster, at a fraction of the cost.
FOR MORE INFORMATION
– Web www.selexis.com
– LinkedIn www.linkedin.com/company/selexis-sa
– Twitter www.twitter.com/SelexisSA
– Facebook www.facebook.com/SelexisSA
Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com
Media Inquiries for Berkeley Lights
Nicole Goelz
CG Life
+1 858-457-2436 ext. 2014
ngoelx@cglife.com
Record changed: 2019-06-24 |
Advertisement
More documents for JSR Corporation (Group)
- [1] Crown Bioscience, Inc.. (4/4/23). "Press Release: Crown Bioscience Announces Transaction Closing of Indivumed’s Service Business and Supporting Biobank". San Diego, CA....
- [2] Indivumed GmbH. (1/25/23). "Press Release: Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank". San Diego, CA & Hamburg....
- [3] Selexis S.A.. (5/2/22). "Press Release: JSR Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA". Sunnyvale, CA....
- [4] Selexis S.A.. (3/18/21). "Press Release: SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program". Geneva....
- [5] Selexis S.A.. (10/20/20). "Press Release: JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland". Sunnyvale, CA....
- [6] Selexis S.A.. (10/16/20). "Press Release: Selexis Names Biopharmaceutical Executive Dirk Lange as New Chief Executive Officer". Geneva....
- [7] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
- [8] Selexis S.A.. (6/20/19). "Press Release: Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing". Cambridge & Geneva....
- [9] Selexis S.A.. (3/28/19). "Press Release: Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines". Geneva....
- [10] Selexis S.A.. (1/9/19). "Press Release: Selexis Expands Strategic Immuno-Oncology Alliance with Agenus". Geneva....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top